Cyclo Therapeutics Announces Data from Ongoing Niemann-Pick Disease Type C1 (NPC1) Trial
Cyclo Therapeutics, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Category: CD derivatives
Ototoxicity of cyclodextrin derivatives
There are two possible mechanisms behind the ototoxicity of 2-hydroxypropyl-β-cyclodextrin (HPBCD) treatment. One is : the possible interaction of HPBCD
History of Cyclodextrin Nanosponges
In the series of historical reviews recently published (https://cyclodextrinnews.com/2020/05/25/the-contribution-of-franz-schardinger-to-cyclodextrins/ and https://cyclodextrinnews.com/2020/05/27/the-history-of-sulfobutylether-beta-cyclodextrin/) also this historical overview on nanosponges deserves attention. Cyclodextrin-based
Cyclodextrin nanosponges for organic toxic molecule removal
Chronic Kidney Disease (CKD) is a global health problem that causes serious economic burden for countries and patients, besides having
Cyclodextrin dimers to treat atherosclerotic plaques by targeting various forms of cholesterol
SENS Research Foundation (USA, California) filed a PCT patent application (WO2020142716) that was recently published. In the invention, a new class
Cyclodextrins in first-line defense against COVID-19
Medical press published the news on the research at the University of Southern California (USC) Dr. Allen and Charlotte Ginsburg
Methyl BCD for axon regeneration after injury – PNAS cover paper
The cover paper of PNAS (1) presents a concept for promoting the neuronal regenerative potential by engineering the expression of
Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer’s Patient
Cyclo Therapeutics, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C
Gilead to Initiate Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years
Set-up of an upcoming clinicl trial has been posted with the primary objectives of this study are to evaluate the
Underdog Pharmaceuticals Announces MD.USE Partnership and Technology Acquisition
Underdog Pharmaceuticals, Inc., a pharmaceutical company designing engineered cyclodextrins to address atherosclerosis and other serious diseases of aging, has completed